A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

People who took Zepbound had greater reductions in waist circumference and body weight, a study found.Fact checked by Nick ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

Microdosing isn’t just popular for psychedelics. Some consumers are taking smaller than standard doses of GLP-1s—the popular ...

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...